Loading clinical trials...
Loading clinical trials...
Assessment of ERG Components to Discriminate Between Schizophrenia and Bipolar Disorder Type I
This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis. The prediction models are diaMentis proprietary software used as an ERG-based diagnostic test (classified as a Software as Medical Device, SaMD) to support the diagnosis of schizophrenia and bipolar disorder type I. They involve the processing and analysis of specific retinal biosignatures (RSPA) with the support of statistical and mathematical modelling processes e.g. machine learning and statistical learning.
The technology under development by diaMentis is defined as a Software as a Medical Device (SaMD); it will be used in combination with an electroretinogram (ERG). This study will be performed using three different ERG devices, currently marketed and cleared by the health authorities (Espion, UTAS and RETeval) to support the analytical, scientific and performance validity of the SaMD. Anomalies detected by ERG provide an objective measure that may reflect specific underlying dysfunctions in patients and thus hold promise to confirm relevant biosignatures in psychiatric disorders. Significant differences between patients with SZ, BPI and control subjects have been found despite confounding factors; this trial is required to better define the impact of patient characteristics on ERG features with a potential to refine the interpretation of results. This is a multicenter study. Three hundred subjects will be enrolled into three groups: 100 SZ patients, 100 BPI patients and 100 control subjects (healthy volunteers). The primary objective is to further characterize the ERG components in SZ and BPI patients in order to develop prediction models that discriminate each pathology. The secondary objectives are the evaluation of the repeatability and reproducibility of the analysis of the ERG components in control subjects, the assessment of the reliability of ERG prediction score for patients following a repeat test, and the evaluation of the impact of different ERG devices on the data generated and the prediction models.
Age
18 - 50 years
Sex
ALL
Healthy Volunteers
Yes
Collaborative Neuroscience Research LLC
Garden Grove, California, United States
Synergy San Diego
Lemon Grove, California, United States
Collaborative Neuroscience Research LLC
Torrance, California, United States
Segal trials West Broward Outpatient Site
Lauderhill, Florida, United States
Segal Trials Miami Lakes Medical Research
Miami Lakes, Florida, United States
McLean Hospital
Belmont, Massachusetts, United States
Rutgers University Behavioral HealthCare
Piscataway, New Jersey, United States
The Zucker Hillside Hospital
Glen Oaks, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Richmond Behavioral Associates
Staten Island, New York, United States
Start Date
July 5, 2018
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
August 22, 2025
300
ESTIMATED participants
ERG assessment (RSPA)
DEVICE
Lead Sponsor
diaMentis Inc.
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions